Our previous work and other colleagues’ studies showed that MTDH is an oncogene and a trigger that activates PI3K, MAPK, and WNT pathway in head and neck cancer and other types of cancer (Emdad et al., 2016; Robertson et al., 2018; Yoo et al., 2011; Yu et al., 2014), which indicates MTDH would serve as an unfavorable prognosis indicator for patients with cancer. This evidence concerns the gene MTDH and head and neck cancer.